Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
6.89M
-
Number of holders
-
26
-
Total 13F shares, excl. options
-
2.08M
-
Shares change
-
+64.1K
-
Total reported value, excl. options
-
$6.83M
-
Value change
-
+$211K
-
Number of buys
-
8
-
Number of sells
-
-4
-
Price
-
$3.29
Significant Holders of Aprea Therapeutics, Inc. - Common Stock (APRE) as of Q4 2024
26 filings reported holding APRE - Aprea Therapeutics, Inc. - Common Stock as of Q4 2024.
Aprea Therapeutics, Inc. - Common Stock (APRE) has 26 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.08M shares
of 6.89M outstanding shares and own 30.16% of the company stock.
Largest 10 shareholders include AIGH Capital Management LLC (539K shares), Sio Capital Management, LLC (277K shares), SPHERA FUNDS MANAGEMENT LTD. (270K shares), Nantahala Capital Management, LLC (206K shares), VANGUARD GROUP INC (174K shares), Stonepine Capital Management, LLC (149K shares), DAFNA Capital Management LLC (137K shares), Exome Asset Management LLC (128K shares), GEODE CAPITAL MANAGEMENT, LLC (42.7K shares), and MORGAN STANLEY (36.8K shares).
This table shows the top 26 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.